Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert G Feldman

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 12, 2023
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical ConditionsRobert G Feldman, Raffaele Antonelli-Incalzi, Katie Steenackers, et al.
Infection and Immunity|February 21, 2002
Identification of major outer surface proteins of Streptococcus agalactiaeMartin J G Hughes, Joanne C Moore, Jonathan D Lane, et al.
The Lancet. Respiratory Medicine|April 17, 2025
Efficacy, safety, and immunogenicity of the AS01<sub>E</sub>-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trialMichael G Ison, Alberto Papi, Eugene Athan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 22, 2024
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV SeasonsMichael G Ison, Alberto Papi, Eugene Athan, et al.
Open Forum Infectious Diseases|April 17, 2023
Respiratory Syncytial Virus Disease Burden in Community-Dwelling and Long-Term Care Facility Older Adults in Europe and the United States: A Prospective StudySílvia Narejos Pérez, Josep María Ramón Torrell, Airi Põder, et al.
Infection and Immunity|June 18, 2002
Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteersZoë Hindle, Steven N Chatfield, Jo Phillimore, et al.
American Journal of Human Genetics|March 29, 2002
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD studyAnita L DeStefano, Mark F Lew, Lawrence I Golbe, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 12, 2023
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical ConditionsRobert G Feldman, Raffaele Antonelli-Incalzi, Katie Steenackers, et al.
Infection and Immunity|February 21, 2002
Identification of major outer surface proteins of Streptococcus agalactiaeMartin J G Hughes, Joanne C Moore, Jonathan D Lane, et al.
The Lancet. Respiratory Medicine|April 17, 2025
Efficacy, safety, and immunogenicity of the AS01<sub>E</sub>-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trialMichael G Ison, Alberto Papi, Eugene Athan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 22, 2024
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV SeasonsMichael G Ison, Alberto Papi, Eugene Athan, et al.
Open Forum Infectious Diseases|April 17, 2023
Respiratory Syncytial Virus Disease Burden in Community-Dwelling and Long-Term Care Facility Older Adults in Europe and the United States: A Prospective StudySílvia Narejos Pérez, Josep María Ramón Torrell, Airi Põder, et al.
Infection and Immunity|June 18, 2002
Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteersZoë Hindle, Steven N Chatfield, Jo Phillimore, et al.
American Journal of Human Genetics|March 29, 2002
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD studyAnita L DeStefano, Mark F Lew, Lawrence I Golbe, et al.
Pageof 2